Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jiangxi Rimag Group CoFRA:RD9 +3.42%14 Median PS Value is €0.00 as of Aug. 08, 2026. GuruFocus rates FRA:RD9 with a GF Score™ of 14/100. The stock has 6 warning signs investors should review. Among 261 Healthcare Providers & Services companies, Jiangxi Rimag Group Co ranks worse than 383141.38% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Jiangxi Rimag Group Co's Median PS Value or its related term are showing as below:
FRA:RD9's Price-to-Median-PS-Value is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 0.73 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Jiangxi Rimag Group Co (FRA:RD9) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Jiangxi Rimag Group Co's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.4995
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangxi Rimag Group Co Median PS Value Related Terms
Jiangxi Rimag Group Co Median PS Value Historical Data
* Premium members only.
The historical data trend for Jiangxi Rimag Group Co's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:RD9 vs HCA, THC, DVA: Median PS Value Comparison
For the Medical Care Facilities subindustry, Jiangxi Rimag Group Co's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangxi Rimag Group Co Price-to-Median-PS-Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Jiangxi Rimag Group Co's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Jiangxi Rimag Group Co's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Jiangxi Rimag Group Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.285.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangxi Rimag Group Co (FRA:RD9) has a Median PS Value of €0.00 as of Aug. 08, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Jiangxi Rimag Group Co and its competitors. According to the industry distribution chart, Jiangxi Rimag Group Co ranks #999999 out of 261 companies in the Healthcare Providers & Services industry.
Is Jiangxi Rimag Group Co's Median PS Value too high?
Jiangxi Rimag Group Co's current Median PS Value is €0.00. Based on the distribution chart, Jiangxi Rimag Group Co ranks #999999 out of 261 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Jiangxi Rimag Group Co has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Jiangxi Rimag Group Co's Median PS Value compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Jiangxi Rimag Group Co ranks #999999 out of 261 companies for Median PS Value. This places Jiangxi Rimag Group Co in the lower half of its industry. The industry median Median PS Value is 0.73. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Healthcare Providers & Services company?
The median Median PS Value among Healthcare Providers & Services companies is 0.73, based on 261 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Jiangxi Rimag Group Co and its competitors. For the Healthcare Providers & Services industry, the median Median PS Value is 0.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangxi Rimag Group Co's current Median PS Value is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangxi Rimag Group Co stock overvalued right now?
Jiangxi Rimag Group Co (FRA:RD9) has a current Median PS Value of €0.00. The current Median PS Value is €0.00. Jiangxi Rimag Group Co's overall GF Score™ is 14/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Jiangxi Rimag Group Co (FRA:RD9), the current Median PS Value is €0.00 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jiangxi Rimag Group Co Ltd is a medical group specializing in medical imaging in China. The company generates revenue through these segments: Imaging Center Services, Imaging Solution Services, and Digital-intelligence services. The Imaging Center Services include examination and diagnostic services to patients and other healthcare consumers via its flagship imaging centers, such as MRI, CT, PET, X-ray, ultrasound and mammography. Majority of the revenue comes from Imaging center services. Geographically, the company operates in Chinese Mainland and Overseas (including Hong Kong and Macau). It generates maximum revenue from Chinese Mainland.
14GF Score
Get the complete analysis for FRA:RD9
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RD9 has been successfully added to your 
